What Zentalis Pharmaceuticals, Inc. does.

We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC. We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, has the potential to support an accelerated approval, subject to U.S. Food and Drug Administration, or FDA, review. Azenosertib also has broad franchise potential beyond Cyclin E1-positive PROC. We exclusively in-license or solely own worldwide development and commercialization rights to azenosertib.

• Rapidly advance the clinical development of azenosertib as a monotherapy toward first regulatory approval in Cyclin E1-positive PROC . We believe azenosertib has the potential to set a new standard of care in patients with Cyclin E1-positive PROC. Many patients with PROC receive single-agent chemotherapy, which has modest clinical benefits. In January 2025, we disclosed a significant amount of clinical data showing an objective response rate, or ORR, of over 30% and a manageable safety profile in patients with Cyclin E1-positive PROC who received azenosertib at our primary dose-of-interest, 400 mg QD 5:2 (single daily dose on an intermittent schedule of five days on and two days off). We completed enrollment in Part 2a of our Phase 2 DENALI clinical trial of azenosertib in patients with Cyclin E1-positive PROC in 2025 and anticipate a topline readout from the trial by year end 2026. DENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review.

Revenue and profit, by fiscal year.

More on ZNTL.

• Zentalis Pharmaceuticals, Inc. summary
• Zentalis Pharmaceuticals, Inc. financial statements
• Zentalis Pharmaceuticals, Inc. key metrics
• Zentalis Pharmaceuticals, Inc. health scores and style box
• Zentalis Pharmaceuticals, Inc. earnings
• Zentalis Pharmaceuticals, Inc. dividends
• Zentalis Pharmaceuticals, Inc. valuation
• Zentalis Pharmaceuticals, Inc. ownership and insiders
• Zentalis Pharmaceuticals, Inc. peers

Figures from Zentalis Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.